BATHROOM & KITCHEN TODAY08 Apr 2020
Interplay of medical technology and excellent design enables reliable Covid-19 rapid test
Views: 21

The coronavirus SARS-CoV-2 is posing major challenges for healthcare systems and medical institutions worldwide. An ability to rapidly diagnose the virus is of invaluable help in curbing its exponential spread in many countries. Bosch’s new, fully automated rapid test for COVID-19 can help medical facilities such as doctors’ offices, hospitals, laboratories, and health centers make fast diagnoses.

The rapid molecular diagnostic test runs on the Vivalytic analysis device from Bosch Healthcare Solutions. “We want the Bosch rapid COVID-19 test to play a part in containing the coronavirus pandemic as quickly as possible. It will speed up the identification and isolation of infected patients,” says Dr. Volkmar Denner, chairman of the board of management of Robert Bosch GmbH.

Developed in just six weeks, the rapid test can detect a SARS-CoV-2 coronavirus infection in patients in under two and a half hours — measured from the time the sample is taken to the time the result arrives. Another advantage of the rapid test is that it can be performed directly at the point of care. This eliminates the need to transport samples, which takes up valuable time. It also means patients quickly gain certainty about their state of health, while allowing infected individuals to be identified and isolated immediately. With the tests currently in use, patients must usually wait one to two days for a result. “Time is of the essence in the fight against coronavirus. Reliable, rapid diagnosis directly on site with no back and forth — that is the great advantage of our solution, which we see as another example of technology that is ‘Invented for life,’” Denner says.

Bosch’s rapid test is one of the world’s first fully automated molecular diagnostic tests that can be used directly by all medical institutions. What’s more, it allows a single sample to be tested not just for COVID-19 but also for nine other respiratory diseases, including influenza A and B, simultaneously. “The special feature of the Bosch test is that it offers differential diagnosis, which saves doctors the additional time needed for further tests. It also provides them with a reliable diagnosis quickly so they can then begin suitable treatment faster,” says Marc Meier, president of Bosch Healthcare Solutions GmbH. The newly developed test will be available in Germany starting in April, with other markets in Europe and elsewhere to follow.